Radiotherapy in Geriatric Lung Cancer Patients

radyasyon_onkolojisi_102

Merve ŞAHİNa , Berrin BENLİ YAVUZb
aErzurum City Hospital, Clinic of Radiation Oncology, Erzurum, Türkiye
bNecmettin Erbakan University, Faculty of Medicine, Department of Radiation Oncology, Konya, Türkiye

Şahin M, Benli Yavuz B. Radiotherapy in geriatric lung cancer patients. In: Metcalfe E, ed. Radiotherapy and Current Developments in Geriatric Cancers. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.25-32.

ABSTRACT
Management of elderly patients is challenging. Elderly patients with non-small cell (NSCLC) and small cell lung cancer (SCLC) are underrepresented in most studies. In these patients, chronologic age should not be the only determinant of treatment decisions. Age-related physiological changes may affect the tolerability of cancer treatment, and patient physiology should be considered in treatment decisions. Comprehensive geriatric evaluation may reduce treatment toxicities and failures. It has been showmn in most studies that older patients have similar oncologic outcomes when treated according to stage compared to younger patients. Therefore, treatment should be individualized and evaluated with a multidisciplinary approach to avoid under or over-treatment in elderly patients. In patients who can tolerate treatment, treatment options include surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapy.

Keywords: Elderly; lung cancer; radiotherapy

Referanslar

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [Crossref]  [PubMed]
  2. SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. [updated: 2023 Nov 16; cited 2024 Mar 20]. Available from: Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries. [Link]
  3. Decoster L, Kenis C, Schallier D, Vansteenkiste J, Nackaerts K, Vanacker L, et al. Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. Lung. 2017;195(5):619-26. [Crossref]  [PubMed]
  4. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-65. [Crossref]  [PubMed]
  5. Gajra A, Akbar SA, Din NU. Management o-f Lung Cancer in the Elderly. Clin Geriatr Med. 2016;32(1):81-95. [Crossref]  [PubMed]
  6. Cope DG, Reb A, Schwartz R, Simon J. Older Adults With Lung Cancer: Assessment, Treatment Options, Survivorship Issues, and Palliative Care Strategies. Clin J Oncol Nurs. 2018;22(6):26-35.
  7. Barta JA, Zinner RG, Unger M. Lung Cancer in the Older Patient. Clin Geriatr Med. 2017;33(4):563-77. [Crossref]  [PubMed]
  8. Sert F, Metcalfe E, Erkal EY, Alço G, Bakkal BH, Özyiğit G. Evalution of the Radiation Ongologists' Awareness and Needs about Geriatric Oncology: TROD-13-001 Study.Turk J Oncol. 2023;38(3):295-300. [Crossref]
  9. Blanco R, Maestu I, de la Torre MG, Cassinello A, Nuñez I. A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol. 2015;26(3):451-63. [Crossref]  [PubMed]
  10. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023;388(6):489-98. [Crossref]  [PubMed]  [PMC]
  11. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012;84(5):1060-70. [Crossref]  [PubMed]  [PMC]
  12. NCCN guidelines: Non Small Cell Lung Cancer. NCCN clinical practice guidelines in oncology 2024, version 4,2024. Available at: Acccessed March 12, 2024. [Link]
  13. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94-100. [Crossref]  [PubMed]
  14. Nanda RH, Liu Y, Gillespie TW, Mikell JL, Ramalingam SS, Fernandez FG, et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. Cancer. 2015;121(23):4222-30. [Crossref]  [PubMed]
  15. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630-7. [Crossref]  [PubMed]
  16. Watanabe K, Katsui K, Sugiyama S, Yoshio K, Kuroda M, Hiraki T, et al. Lung stereotactic body radiation therapy for elderly patients aged≥80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study. Radiat Oncol. 2021;16(1):39. [Crossref]  [PubMed]  [PMC]
  17. Yang CJ, Brown AB, Deng JZ, Lui NS, Backhus LM, Shrager JB, et al. The Oldest Old: A National Analysis of Outcomes for Patients 90 Years or Older With Lung Cancer. Ann Thorac Surg. 2020;109(2):350-7. [Crossref]  [PubMed]
  18. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol. 2011;101(2):240-4. [Crossref]  [PubMed]
  19. Bayman N, Alam N, Faivre-Finn C. Radiotherapy for lung cancer in the elderly. Lung Cancer. 2010;68(2):129-36. [Crossref]  [PubMed]
  20. Atagi S, Mizusawa J, Ishikura S, Takahashi T, Okamoto H, Tanaka H, et al. Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). Clin Lung Cancer. 2018;19(5):e619-e27. [Crossref]  [PubMed]
  21. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-90. [Crossref]  [PubMed]
  22. Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28(4):777-83. [Crossref]  [PubMed]
  23. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-11. Erratum in: J Clin Oncol. 2022;40(17):1965. [Crossref]  [PubMed]  [PMC]
  24. Radovic M, Kanesvaran R, Rittmeyer A, Früh M, Minervini F, Glatzer M, et al. Multidisciplinary treatment of lung cancer in older patients: A review. J Geriatr Oncol. 2019;10(3):405-10. [Crossref]  [PubMed]
  25. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004-14. [Crossref]  [PubMed]
  26. Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol. 2004;22(5):801-10. [Crossref]  [PubMed]
  27. American Cancer Society. Key Statistics for Lung Cancer. Atlanta GACS. Accessed July 15, 2022. [Link]
  28. SEER cancer statistics factsheets: lung and bronchus cancer. National Cancer Institute. Bethesda. [Link]
  29. Bunn PA Jr, Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol. 1997;24(2 Suppl 7):S7-69-S7-74.
  30. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618-24. [Crossref]  [PubMed]
  31. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890-5. [Crossref]  [PubMed]
  32. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265-71. [Crossref]  [PubMed]
  33. Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E; ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi99-105. [Crossref]  [PubMed]
  34. Quon H, Shepherd FA, Payne DG, Coy P, Murray N, Feld R, et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;43(1):39-45. [Crossref]  [PubMed]
  35. Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol. 1996;14(3):821-8. [Crossref]  [PubMed]
  36. Yuen AR, Zou G, Turrisi AT, Sause W, Komaki R, Wagner H, et al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000;89(9):1953-60. [Crossref]  [PubMed]
  37. Schild SE, Stella PJ, Brooks BJ, Mandrekar S, Bonner JA, McGinnis WL, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer. 2005;103(11):2349-54. [Crossref]  [PubMed]
  38. Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD et al. Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer. J Clin Oncol. 2015;33(36):4240-6. [Crossref]  [PubMed]  [PMC]
  39. Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U et al. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. Acta Oncol. 2016; 55(11):1349-54. [Crossref]  [PubMed]
  40. Noguchi T, Mochizuki H, Yamazaki M, Kawate E, Suzuki Y, Sato T, et al. A retrospective analysis of clinical outcomes of patients older than or equal to 80 years with small cell lung cancer. J Thorac Oncol. 2010;5(7):1081-7. [Crossref]  [PubMed]
  41. Killingberg KT, Grønberg BH, Slaaen M, Kirkevold Ø, Halvorsen TO. Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC. J Thorac Oncol. 2023;18(6):803-12. [Crossref]  [PubMed]
  42. Stinchcombe TE, Fan W, Schild SE, Vokes EE, Bogart J, Le QT, et al. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2019;125(3):382-90. [Crossref]  [PubMed]  [PMC]
  43. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer. 1998;82(5):836-41. [Crossref]
  44. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116-25. [Crossref]  [PubMed]
  45. Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V et al. Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. J Thorac Oncol. 2019;14(1):63-71. [Crossref]
  46. Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1993;11(7):1230-40. [Crossref]  [PubMed]
  47. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol. 1999;17(7):2092-9. [Crossref]  [PubMed]
  48. Yee D, Butts C, Reiman A, Joy A, Smylie M, Fenton D, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol. 2012;102(2):234-8. [Crossref]  [PubMed]
  49. Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36-42. [Crossref]  [PubMed]
  50. Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer. 2017;108:150-3. [Crossref]  [PubMed]
  51. Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017;12(10):1561-70. [Crossref]  [PubMed]  [PMC]
  52. Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476-84. [Crossref]  [PubMed]
  53. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M et al. EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357(7):664-72. [Crossref]  [PubMed]
  54. Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer. 2009;115(4):842-50. [Crossref]  [PubMed]
  55. Rule WG, Foster NR, Meyers JP, Ashman JB, Vora SA, Kozelsky TF, et al. Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol. 2015;6(2):119-26. [Crossref]  [PubMed]  [PMC]
  56. Farooqi AS, Holliday EB, Allen PK, Wei X, Cox JD, Komaki R. Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit? Radiother Oncol. 2017;122(2):307-12. [Crossref]  [PubMed]  [PMC]
  57. Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663-671. [Crossref]  [PubMed]
  58. Chen Y, Wang Y, Ren F, Huang Z, Tan B, Zhao Z, et al. Prophylactic cranial irradiation (PCI) versus active surveillance in patients with limited-stage small cell lung cancer: a retrospective, multicentre study. Respir Res. 2022;23(1):274. [Crossref]